Investigational drug for recent ischemic stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests an investigational injectable drug called LT3001 that may help dissolve blood clots in the brain after a stroke. It is given within 24 hours of stroke onset, and the goal is to reduce disability and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had an ischemic stroke (a blockage in a brain blood vessel) that causes noticeable problems like weakness or trouble speaking.
- Your stroke must be moderate in severity, as measured by a standard scale (score between 6 and 25).
- You must be able to receive the study drug within 24 hours of your stroke starting.
- You cannot have had clot-busting medicine or a procedure to remove the clot for this stroke.
- You should not have had a prior stroke, heart attack, or major head injury before this one.
- Women who can have children and men with partners who can have children must agree to use effective birth control during the study and for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests LT3001 to improve recovery after an acute ischemic stroke (a stroke caused by blocked blood flow). It is designed for people who can be treated within 24 hours of symptom onset and who meet specific safety and health requirements.
This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.
This trial tests a new drug called BB-031 for people who have had a stroke caused by a blocked blood vessel in the brain. The drug may help restore blood flow and reduce damage if given within 24 hours of symptoms starting.
This trial tests a medication called tirofiban given intravenously after standard thrombolysis to see if it improves recovery in people with acute ischemic stroke. It is for those whose symptoms have not improved or are getting worse after initial treatment.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the blocked blood vessel in the brain can help people with a medium-sized vessel occlusion stroke. The drug may help restore blood flow and reduce disability, and it is given within 24 hours of symptom onset.
This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.